Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CellaVision ABCLVSF 85 Receivables Turnover is 1.57 as of Mar. 2026. GuruFocus rates CLVSF with a GF Score™ of 85/100 and a GF Value™ of $22.02 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 812 Medical Devices & Instruments companies, CellaVision AB ranks better than 61.82% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. CellaVision AB's Revenue for the
three
months ended in Mar. 2026 was $17.86 Mil. CellaVision AB's average Accounts Receivable for the
three
months ended in Mar. 2026 was $11.38 Mil.
Hence, CellaVision AB's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.57.
CellaVision AB (OTCPK:CLVSF) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
CellaVision AB Receivables Turnover Related Terms
CellaVision AB Receivables Turnover Historical Data
* Premium members only.
The historical data trend for CellaVision AB's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CLVSF vs ABT, SYK, MDT: Receivables Turnover Comparison
For the Medical Devices subindustry, CellaVision AB's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CellaVision AB Receivables Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, CellaVision AB's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where CellaVision AB's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CellaVision AB (CLVSF) has a Receivables Turnover of 1.57 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on CellaVision AB and its competitors. According to the industry distribution chart, CellaVision AB ranks #310 out of 812 companies in the Medical Devices & Instruments industry, placing it in the top 38.2%.
Is CellaVision AB's Receivables Turnover too high?
CellaVision AB's current Receivables Turnover is 1.57. The Medical Devices & Instruments industry median Receivables Turnover is 5.51. CellaVision AB's value of 1.57 is 71.5% below this industry median. Based on the distribution chart, CellaVision AB ranks #310 out of 812 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, CellaVision AB has a GF Score™ of 85/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CellaVision AB's Receivables Turnover compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, CellaVision AB ranks #310 out of 812 companies for Receivables Turnover. This puts CellaVision AB in the upper half of its industry. The industry median Receivables Turnover is 5.51. CellaVision AB's value of 1.57 is 71.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Devices & Instruments company?
The median Receivables Turnover among Medical Devices & Instruments companies is 5.51, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CellaVision AB's current Receivables Turnover of 1.57 is 71.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on CellaVision AB and its competitors. For the Medical Devices & Instruments industry, the median Receivables Turnover is 5.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CellaVision AB's current Receivables Turnover is 1.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CellaVision AB stock overvalued right now?
Based on GuruFocus' analysis, CellaVision AB (CLVSF) is currently considered Significantly Undervalued. The stock's GF Value™ is $22.02, compared to a current price of $14.00 — trading 36.4% below its estimated fair value. The current Receivables Turnover is 1.57 and 71.5% below the Medical Devices & Instruments industry median of 5.51. CellaVision AB's overall GF Score™ is 85/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For CellaVision AB (CLVSF), the current Receivables Turnover is 1.57 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CellaVision AB (CLVSF) Overvalued in 2026?
Based on GuruFocus' analysis, CellaVision AB stock appears to be undervalued.
The current stock price of $14.00 is trading 36.4% below its estimated GF Value™ of $22.02.
GuruFocus considers CellaVision AB to be Significantly Undervalued.
Key valuation signals for CLVSF:
Receivables Turnover: 1.57
GF Value™: $22.02 vs. price of $14.00 (36.4% below fair value)
Industry Position: 71.5% below the Medical Devices & Instruments median (#310 of 812)
No single metric tells the full story. See the CLVSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CellaVision AB is engaged in developing and selling instruments, software, and reagents for blood and body fluid analysis. The company automates parts of the sample preparation process and replaces manual microscopes with instruments based on digital image analysis technology and artificial intelligence. The solutions contribute to more effective workflows and higher quality in laboratory medicine. The product offer consists of products and solutions for standardized laboratory diagnostics and improved performance for cellular image processing and systems for digital microscopy in hematology, consisting of reagents, instruments, and supplementary software and peripheral equipment.
85GF Score
Get the complete analysis for CLVSF
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLVSF has been successfully added to your 
